Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer blood tests. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/28/23 | $140,000,000 | Series B |
Catalyst Group Flagship Pioneering M&G Investments Partners Investment Co. Pictet | undisclosed |
